Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3
ASCO 2026
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD-3 trial, which evaluated tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in patients with unresectable embolization-eligible hepatocellular carcinoma (LBA4000).
The ASCO Post Staff
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).
The ASCO Post Staff
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).
The ASCO Post Staff
Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004).
The ASCO Post Staff
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
The ASCO Post Staff
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both premenopausal and postmenopausal populations (Abstract 502).
